Trials / Terminated
TerminatedNCT02175745
18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas
18F-FDOPA PET/CT or PET/MRI in Patients With Gliomas
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Erik Mittra · Academic / Other
- Sex
- All
- Age
- 16 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.
Detailed description
This clinical trial compares fluorine F-18 fluoro-dihydroxyphenylalanine (18F-fluorodopa or 18F-FDOPA) positron emission tomography (PET) with standard magnetic resonance imaging (MRI) in measuring tumors in patients with glioma that is newly diagnosed or recurrent (has returned). 18F-FDOPA is a radioactive drug that binds to tumor cells and is captured in images by PET. Computed tomography (CT) and MRI are used with PET to describe information regarding the function, location, and size of the tumor. PET/CT or PET/MRI may be more accurate than standard MRI in helping doctors find and measure brain tumors.
Conditions
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- Adult Brain Stem Glioma
- Adult Diffuse Astrocytoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Adult Mixed Glioma
- Adult Oligodendroglioma
- Adult Pilocytic Astrocytoma
- Adult Pineal Gland Astrocytoma
- Adult Subependymal Giant Cell Astrocytoma
- Childhood High-grade Cerebellar Astrocytoma
- Childhood High-grade Cerebral Astrocytoma
- Childhood Low-grade Cerebellar Astrocytoma
- Childhood Low-grade Cerebral Astrocytoma
- Recurrent Adult Brain Tumor
- Recurrent Childhood Anaplastic Astrocytoma
- Recurrent Childhood Anaplastic Oligoastrocytoma
- Recurrent Childhood Anaplastic Oligodendroglioma
- Recurrent Childhood Brain Stem Glioma
- Recurrent Childhood Cerebellar Astrocytoma
- Recurrent Childhood Cerebral Astrocytoma
- Recurrent Childhood Diffuse Astrocytoma
- Recurrent Childhood Fibrillary Astrocytoma
- Recurrent Childhood Gemistocytic Astrocytoma
- Recurrent Childhood Giant Cell Glioblastoma
- Recurrent Childhood Glioblastoma
- Recurrent Childhood Gliomatosis Cerebri
- Recurrent Childhood Gliosarcoma
- Recurrent Childhood Oligoastrocytoma
- Recurrent Childhood Oligodendroglioma
- Recurrent Childhood Pilomyxoid Astrocytoma
- Recurrent Childhood Protoplasmic Astrocytoma
- Recurrent Childhood Subependymal Giant Cell Astrocytoma
- Recurrent Childhood Visual Pathway and Hypothalamic Glioma
- Recurrent Childhood Visual Pathway Glioma
- Untreated Childhood Anaplastic Astrocytoma
- Untreated Childhood Anaplastic Oligoastrocytoma
- Untreated Childhood Anaplastic Oligodendroglioma
- Untreated Childhood Brain Stem Glioma
- Untreated Childhood Cerebellar Astrocytoma
- Untreated Childhood Cerebral Astrocytoma
- Untreated Childhood Diffuse Astrocytoma
- Untreated Childhood Fibrillary Astrocytoma
- Untreated Childhood Gemistocytic Astrocytoma
- Untreated Childhood Giant Cell Glioblastoma
- Untreated Childhood Glioblastoma
- Untreated Childhood Gliomatosis Cerebri
- Untreated Childhood Gliosarcoma
- Untreated Childhood Oligoastrocytoma
- Untreated Childhood Oligodendroglioma
- Untreated Childhood Pilomyxoid Astrocytoma
- Untreated Childhood Protoplasmic Astrocytoma
- Untreated Childhood Subependymal Giant Cell Astrocytoma
- Untreated Childhood Visual Pathway and Hypothalamic Glioma
- Untreated Childhood Visual Pathway Glioma
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 18F-fluoro-dihydroxyphenylalanine | Administered intravenously (IV) |
| PROCEDURE | Positron emission tomography (PET) | Component of an 18F-FDOPA PET/CT or PET/MRI scan |
| PROCEDURE | Computed tomography (CT) | Component of an 18F-FDOPA PET/CT |
| PROCEDURE | Magnetic resonance imaging | Component of an 18F-FDOPA PET/MRI |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2015-08-01
- Completion
- 2015-12-01
- First posted
- 2014-06-26
- Last updated
- 2017-03-20
- Results posted
- 2017-03-20
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02175745. Inclusion in this directory is not an endorsement.